How Much Can Merck's Oncology Drugs' Revenue Grow Over The Next Three Years?

June 08, 2019   |   June 2019 Bond Updates
Merck’s (NYSE:MRK) oncology drugs’ revenue could grow at a CAGR of 10.3% from $8.24 billion in 2018 to $10.95 billion in 2021, according to Trefis estimates. This growth will likely be led by higher sales of Keytruda, as well as higher alliance revenues from Lynparaza and Lenvima. Below we discuss..

View more at:
Related News
Home| About us | Contact us